Digital endpoint monitoring in clinical trials: how to strengthen evidence without adding complexity
Introductory Note
This Insight is inspired by the eBook, Building Connected Clinical Trial Ecosystems, which explores how organisations can reduce technology fragmentation, improve interoperability, and create more connected clinical trial environments. The selection criteria outlined below focus specifically on digital endpoint monitoring technologies and how to optimise their use to strengthen evidence while supporting a streamlined trial ecosystem.
Considerations for selecting technologies that strengthen evidence without adding unnecessary complexity
Clinical trials are increasingly dependent on digital health technologies (DHTs) to capture endpoint data. Wearables, connected medical devices, ePROs, home monitoring solutions, telemedicine platforms, and digital biomarkers offer opportunities to collect more continuous, patient-centric, and clinically meaningful data. However, selecting the right technology is becoming more challenging as trial ecosystems grow more complex.
A common mistake is to evaluate endpoint technologies solely on individual functionality. While a device may perform exceptionally well for a specific assessment, it may simultaneously introduce integration challenges, duplicate workflows, additional training requirements, and increased operational burden. The goal should not be to deploy the most technologies, but to create an ecosystem that delivers high-quality data efficiently and consistently.
The first consideration should be interoperability. Endpoint technologies rarely operate in isolation. DHT data must often be combined with information from electronic data capture systems, laboratory platforms, imaging systems, and other DHTs. Solutions that integrate seamlessly into a broader data ecosystem can reduce manual reconciliation, improve oversight, and provide a more complete view of participant outcomes.
Regulatory readiness is equally important. Endpoint assessment technologies must support data integrity, validation, traceability, audit trails, and secure access controls. Novel measurement capabilities are only valuable if the resulting data can withstand regulatory scrutiny and support reliable decision-making throughout the study lifecycle.
Patient and site experience should also influence technology selection. Every additional device, application, login, or workflow introduces potential burden. Technologies that are difficult to use may reduce compliance, increase missing data, and negatively affect retention. The most successful solutions simplify study participation and fit naturally into clinical workflows rather than requiring users to adapt to the technology.
Sponsors should also consider scalability and long-term strategic fit. Technologies selected for a single study may need to support larger, more complex global programmes in the future. Flexible, standards-based solutions help organisations avoid fragmented technology landscapes and create a foundation for future innovation, including AI-enabled analytics and connected digital health ecosystems.
Ultimately, the best endpoint technologies are not necessarily those with the most advanced features, but those that provide reliable clinical data while supporting a connected, scalable, compliant, and user-friendly clinical trial ecosystem. Success should be measured by improved evidence quality, operational efficiency, and participant experience rather than by the number of digital tools deployed.
Key considerations for endpoint technology selection
Managing technology fragmentation across multiple vendors and platforms.
Balancing scientific value against operational complexity.
Achieving interoperability and effective data integration.
Meeting regulatory, validation, and data integrity requirements.
Minimising participant burden and improving usability.
Reducing site training and administrative workload.
Ensuring scalability across study phases and geographies.
Addressing cybersecurity and patient privacy risks.
Selecting technologies based on ecosystem fit rather than standalone performance.
Want to Learn More?
This article explores just one aspect of building a connected clinical trial ecosystem. For a broader discussion on technology integration, data centralisation, interoperability, and reducing operational complexity across clinical trials, download our eBook, Building Connected Clinical Trial Ecosystems.